Scholarlink

<p>Conventionally chemoimmunotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for newly diagnosed mantle cell lymphoma. The role of BTKi is emerging in upfront management of mantle cell lymphoma. It has redefined the role of upfront stem cell transplantation especially with achievement of deep sustained MRD negativity. Elderly population are not eligible for intensive chemotherapy for many reasons especially frailty, poor performance score and associated comorbidities. The use of upfront Ibrutinib and acalabrutinib with Rituximab, Bendamustine (BR) backbone has been studied in these transplant ineligible cohorts in Phase 3 SHINE and ECHO trial respectively. We reported the early outcome, efficacy of second generation BTKi (acalabrutinib) with BR from an Indian perspective.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acalabrutinib Added To Rituximab, Bendamustine (ABR) in Newly Diagnosed High Risk Mantle Cell Lymphoma: an Early Indian Experience

  • 期刊论文

  • 发表日期：

    2025年12月5日

查看全文
  • Tribikram Panda,
  • Reshmi Harikumar Pillai,
  • Nakul Tikare,
  • Swapnil Tripathi,
  • Devasis Panda,
  • Rohan Halder,
  • Vipul Sharad Sheth,
  • Narender Tejwani,
  • Dinesh Bhurani,
  • Narendra Agrawal

摘要

Conventionally chemoimmunotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for newly diagnosed mantle cell lymphoma. The role of BTKi is emerging in upfront management of mantle cell lymphoma. It has redefined the role of upfront stem cell transplantation especially with achievement of deep sustained MRD negativity. Elderly population are not eligible for intensive chemotherapy for many reasons especially frailty, poor performance score and associated comorbidities. The use of upfront Ibrutinib and acalabrutinib with Rituximab, Bendamustine (BR) backbone has been studied in these transplant ineligible cohorts in Phase 3 SHINE and ECHO trial respectively. We reported the early outcome, efficacy of second generation BTKi (acalabrutinib) with BR from an Indian perspective.